Currently, the pharmacoeconomic studies on the treatment of osteoporosis in menopausal women published both at home and abroad mainly concentrate on RANKL inhibitors, bisphosphonates, and other Western medicine preparations. This evidence concerns the gene TNFSF11 and osteoporosis.